West Pharmaceutical Services' Board Authorizes New $1B Share Repurchase Program

On February 17, 2026, the Board of Directors authorized a new share repurchase program for the purchase of up to $1 billion of the Company's common stock.

The number of shares to be repurchased and the timing of any repurchases will depend on factors such as the stock price, economic and market conditions, and corporate and regulatory requirements. The Company may repurchase shares of its common stock from time to time on the open market (including via pre-set trading plans), in privately negotiated transactions, or through other transactions in accordance with applicable securities laws. The share repurchase program does not obligate the Company to acquire any particular amount of common stock, has no expiration date, and it may be suspended or terminated at any time.